SBIR/STTR Research Award
IGF OT IGF SBIR PHASE II TOPIC DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS
Award amount
$1,499,399Program and phase
SBIR · Phase IIAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- GCFREE, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
Within a tumor there are two main cell types mature cancer cells comprising the majority of a tumor and a small population of especially lethal cancer stem cell CSCs resistant to treatment that can cause cancer relapse Thus novel strategies are needed to target and kill not only the majority of mature cancer cells but also the CSCs in order to achieve long term remissions and potential cures Toward this end Siamab Therapeutics Inc has devised a unique approach to target both mature and CSC components of a tumor using a single therapeutic monoclonal antibody mAb that targets a cancer associated cell surface carbohydrate antigen
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis